MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News:
(FR0012596468 – ALSEN) – Sensorion, a biotech company specializing in the treatment of inner ear diseases, today announces that the Board of Directors has appointed Nawal Ouzren as the Company’s new CEO. Laurent Nguyen will support Mrs. Ouzren as advisor to the CEO during the six next months.
With fifteen years of experience in operational and strategic management within the pharmaceutical industry, Nawal Ouzren started out at Baxter, where she was Strategy and Operational Excellence Manager, Quality Operations Director and Senior Director Strategy before becoming Vice President of the BioSimilaires business unit. In 2014, she became Vice President of the Global Hemophilia Franchise at Baxalta, which had been incorporated within the Shire group. In 2016, she took control of the Shire group’s Global Genetic Diseases division, where she supervised all marketing, business and strategy aspects of this global division’s product portfolio.
Laurent Nguyen says: “I am proud of the Sensorion team that has, in five years, enabled a research company to be transformed into a structured biotech listed on the Alternext Paris market. This successful transformation has produced a unique screening platform in the high-potential inner-ear diseases sector and its two first drug candidates, SENS-111 in phase 2 and SENS-401 in phase 1. I think of all the patients suffering from vertigo, hearing loss or tinnitus and am delighted that Nawal will be able to continue the strategy implemented since our IPO, develop structural partnerships and continue to develop drug candidates and take them to market. I will of course continue to be a loyal Sensorion shareholder and wish Nawal every success in this new phase.”
Nawal Ouzren, CEO of SENSORION, adds: “I am very pleased to be joining the senior management of a biotech that has established itself over the last five years through such a distinctive positioning backed by a team with an excellent reputation in the inner ear segment. With my extensive and diversified global experience in drug development, I have been impressed by the progress made by the products in SENSORION’s portfolio, and have seen how the quality of its technological platform and substantial potential of its target markets will enable the Company to continue its success.”
Patrick Langlois, SENSORION’s Chairman, concludes: “On behalf of the entire Board, I would like to thank Laurent for the execution of our strategy undertaken for the transformation of an academic spinoff into a listed mature biotech with a diverse portfolio in high-potential markets and its IPO. Indeed, it is the quality of a more mature biotech and the excellence of its research, thanks to Laurent and his teams, that has helped us attract a talented new executive like Nawal. With her arrival, our new strategic development era will be even more promising.”
- SFAF financial analysts’ MidCap Day, April 18, 2017 in Paris
- Small Cap Event, April 18-19, 2017 in Paris
- Shareholders’ Meeting, May 30, 2017 in Paris
Sensorion specializes in the treatment of pathologies of the inner ear such as acute vertigo, tinnitus and hearing loss. The company was founded by Inserm (the French Institute of Health and Medical Research) and is utilizing its pharmaceutical R&D experience and comprehensive technology platform to develop first-in-class, easy-to-administer, notably orally active, drug candidates for treating and preventing hearing loss and the symptoms of bouts of vertigo and tinnitus. The first two programs are, respectively, in phase I (SENS-401) and phase II (SENS-111) clinical testing. Based in Montpellier, Southern France, Sensorion has received financial support from Bpifrance, through the InnoBio fund, and Inserm Transfert Initiative.
Sensorion has been listed on the Euronext Alternext Paris exchange since April 2015.
ISIN code: FR0012596468
This press release contains certain forward-looking statements concerning Sensorion and its business. Such forward-looking statements are based on assumptions that Sensorion considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the Document de référence registration document filed with the Autorité des marchés financiers (AMF- French Financial Market Authority) on July 28, 2016 under n°R.16-069 and to the development of economic conditions, financial markets and the markets in which Sensorion operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Sensorion or not currently considered material by Sensorion. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Sensorion to be materially different from such forward-looking statements.
This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Sensorion shares in any country. The communication of this press release in certain countries may constitute a violation of local laws and regulations. Any recipient of this press release must inform oneself of any such local restrictions and comply therewith.